iData Insights

Escherichia coli Infections - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 25, 2016 12:22 IST

Escherichia coli Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Escherichia Coli Infections - Pipeline Review, H2 2015, provides an overview of the Escherichia Coli Infectionss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Escherichia Coli Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

Escherichia coli Infections Overview 9

Therapeutics Development 10

Pipeline Products for Escherichia coli Infections - Overview 10

Pipeline Products for Escherichia coli Infections - Comparative Analysis 11

Escherichia coli Infections - Therapeutics under Development by Companies 12

Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 16

Escherichia coli Infections - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Escherichia coli Infections - Products under Development by Companies 20

Escherichia coli Infections - Products under Investigation by Universities/Institutes 23

Escherichia coli Infections - Companies Involved in Therapeutics Development 24

Adenium Biotech ApS 24

Arsanis Biosciences GmbH 25

AstraZeneca Plc 26

AvidBiotics Corp. 27

Bioorganic Research and Services S.A. 28

Cellceutix Corporation 29

Chiesi Farmaceutici SpA 30

Debiopharm International S.A. 31

Emergent BioSolutions Inc. 32

F. Hoffmann-La Roche Ltd. 33

GangaGen Inc. 34

GlaxoSmithKline Plc 35

Immuron Limited 36

Melinta Therapeutics, Inc 37

Microbiotix, Inc. 38

MicuRx Pharmaceuticals, Inc. 39

Mucosis B.V. 40

Navigen Pharmaceuticals, Inc. 41

Nosopharm SAS 42

Novabiotics Limited 43

Nymox Pharmaceutical Corporation 44

Pherecydes Pharma SA 45

Phico Therapeutics Limited 46

Procarta Biosystems Ltd 47

Sanofi Pasteur SA 48

Sealife PHARMA GMBH 49

Sequoia Sciences, Inc. 50

Soligenix, Inc. 51

Syntiron LLC 52

Tetraphase Pharmaceuticals Inc. 53

Trana Discovery, Inc. 54

Varinel, Inc. 55

Escherichia coli Infections - Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

A-3APO - Drug Profile 65

AA-139 - Drug Profile 67

ACE-920 - Drug Profile 68

Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 69

ASN-4 - Drug Profile 70

AvR2-V10 - Drug Profile 72

BIZ-20131 - Drug Profile 74

BIZ-20132 - Drug Profile 75

BIZ-20133 - Drug Profile 76

BNT-006 - Drug Profile 77

CC-1807 - Drug Profile 78

Debio-1454 - Drug Profile 79

Drugs for Bacterial Infections - Drug Profile 80

dusquetide - Drug Profile 81

EcoXyn-4V - Drug Profile 83

enterotoxigenic escherichia coli vaccine - Drug Profile 84

Escherichia coli (whole cell) vaccine - Drug Profile 85

Escherichia coli vaccine - Drug Profile 86

Escherichia coli vaccine - Drug Profile 87

ETEC Vaccine - Drug Profile 88

ETEC vaccine - Drug Profile 89

EV-035 - Drug Profile 90

GN snare - Drug Profile 92

GN-4474 - Drug Profile 93

IMM-363 - Drug Profile 94

INX-201 - Drug Profile 95

JNJ-63871860 - Drug Profile 96

MBX-2319 - Drug Profile 97

MDN-0057 - Drug Profile 98

MRX-V - Drug Profile 100

NBTI-5463 - Drug Profile 101

NOSO-95179 - Drug Profile 102

NP-432 - Drug Profile 103

NXC-4720 - Drug Profile 104

Onc-72 - Drug Profile 105

PMX-1241 - Drug Profile 106

PMX-1278 - Drug Profile 107

PMX-1363 - Drug Profile 108

PMX-1405 - Drug Profile 109

PMX-247 - Drug Profile 110

PMX-843 - Drug Profile 111

PP-0121 - Drug Profile 112

Proteins for Infectious Diseases - Drug Profile 114

PT-4 - Drug Profile 115

Recombinant Protein for Escherichia Coli Infections - Drug Profile 116

RX-05 - Drug Profile 117

RXP-873 - Drug Profile 118

SE-1 - Drug Profile 119

Shigetec - Drug Profile 120

SLP-0901 - Drug Profile 121

SLP-0905 - Drug Profile 122

Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 123

Small Molecules for Bacterial Infections - Drug Profile 124

Small Molecules for Escherichia Coli Infections - Drug Profile 125

Small Molecules for Escherichia coli Infections - Drug Profile 126

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 127

Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 128

Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129

Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 130

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 131

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 132

Synthetic Peptides for Escherichia Coli Infections - Drug Profile 133

TP-6076 - Drug Profile 134

VAR-10100 - Drug Profile 135

Escherichia coli Infections - Recent Pipeline Updates 136

Escherichia coli Infections - Dormant Projects 143

Escherichia coli Infections - Discontinued Products 146

Escherichia coli Infections - Product Development Milestones 147

Featured News & Press Releases 147

Appendix 148

Methodology 148

Coverage 148

Secondary Research 148

Primary Research 148

Expert Panel Validation 148

Contact Us 148

Disclaimer 149

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects